Antivirals publications, 2010–2011

106 Pages·2013·1.02 MB·English

APPENDIX 12
Antivirals publications, 2010–2011
1. 2009. [Black triangle down] Tamiflu – the wrong message? Drug Ther.Bull. 47:97. doi:47/9/97
[pii];10.1136/dtb.2009.08.0034 [doi].
2. 2009. A caution about giving Tamiflu to children. Child Health Alert. 27:4–5.
3. 2009. Antiviral drugs for influenza. Med.Lett.Drugs Ther. 51:89–92.
4. 2009. Campus response to novel influenza H1N1. J.Am.Coll.Health 58:281–289.
doi:U6265414166J437M [pii];10.1080/07448480903482510 [doi].
5. 2009. Case management for influenza. J.Indian Med.Assoc. 107:528–530.
6. 2009. Epidemiology of seasonal, avian and pandemic influenza. J.Indian Med.Assoc. 107:506–507.
7. 2009. Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for
Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University
School of Law in the fall of 2008. Seton.Hall.Law Rev. 39:1103–1109.
8. 2009. Pandemic preparedness. Alta.RN. 65:20–27.
9. 2009. Update on oseltamivir-resistant pandemic A (H1N1)
10. 2009 influenza virus: January 2010. Wkly.Epidemiol.Rec. 85:37–40.
11. 2010. [Technical report on the 2009 influenza A (H1N1) pandemic]. An.Pediatr.(Barc.) 72:81–35.
doi:S1695-4033(09)00614-6 [pii];10.1016/j.anpedi.2009.11.002 [doi].
12. 2010. [Treatment with antiviral agents]. An.Pediatr.(Barc.) 72:81–85. doi:S1695-4033(09)00621-3
[pii];10.1016/j.anpedi.2009.11.009 [doi].
13. 2010. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care – New York
City, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:321–326. doi:mm5911a1 [pii].
14. 2010. A pandemic of hindsight? Nature 465:985. doi:465985a [pii];10.1038/465985a [doi].
15. 2010. Fatal H1N1 infection in an HIV positive woman. Negative flu tests, HIV infection delay
treatment. AIDS Alert. 25:9–10.
16. 2010. Influenza activity – United States and worldwide, June 13–September 25, 2010. MMWR Morb.
Mortal.Wkly.Rep. 59:1270–1273. doi:mm5939a3 [pii].
17. 2010. Outbreak of 2009 pandemic influenza A (H1N1) on a Peruvian Navy ship – June–July 2009.
MMWR Morb.Mortal.Wkly.Rep. 59:162–165. doi:mm5906a3 [pii].
18. 2010. Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents –
three states, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:74–77. doi:mm5903a3 [pii].
19. 2010. Patient education series. Seasonal influenza (the flu). Nursing. 40:33. doi:10.1097/01.
NURSE.0000387238.05776.38 [doi];00152193-201009000-00011 [pii].
20. 2010. Patient information. Influenza. Am.Fam.Physician 82:1097. doi:p722 [pii].
211
WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA
21. 2010. Patients hospitalized with 2009 pandemic influenza A (H1N1) – New York City, May 2009.
MMWR Morb.Mortal.Wkly.Rep. 58:1436–1440. doi:mm5851a2 [pii].
22. 2010. Update: influenza activity – United States, 2009–10 season. MMWR Morb.Mortal.Wkly.Rep.
59:901–908. doi:mm5929a2 [pii].
23. 2010. Update: influenza activity – United States, October 3–December 11, 2010. MMWR Morb.
Mortal.Wkly.Rep. 59:1651–1655. doi:mm5950a4 [pii].
24. 2011. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza
virus A H5N1 to antiinfluenza agents in cell culture]. Antibiot.Khimioter. 56:3–9.
25. 2011. Antiviral drugs for influenza. Med.Lett.Drugs Ther. 53:1–3.
26. 2011. Infectious disease. Antiviral agents for the treatment and chemoprophylaxis of influenza. Ann.
Emerg.Med. 58:299–303. doi:S0196-0644(11)01304-7 [pii];10.1016/j.annemergmed.2011.07.007
[doi].
27. 2011. Recommended composition of influenza virus vaccines for use in the 2011–2012 northern
hemisphere influenza season. Wkly.Epidemiol.Rec. 86:86–90.
28. 2011. Update: influenza activity – United States, October 3, 2010–February 5, 2011. MMWR Morb.
Mortal.Wkly.Rep. 60:175–181. doi:mm6006a4 [pii].
29. Aardema, H., J. E. Tulleken, R. J. van den Biggelaar, B. A. Wolters, C. M. de Jager, C. A. Boucher,
and A. Riezebos-Brilman. 2010. [Fatal pneumonitis due to oseltamivir-resistant new influenza
A(H1N1) in the case of an intensive care patient]. Ned.Tijdschr.Geneeskd. 154:A1634.
30. Abdel-Rahman, S. M., J. G. Newland, and G. L. Kearns. 2011. Pharmacologic considerations for
oseltamivir disposition: focus on the neonate and young infant. Paediatr.Drugs 13:19–31. doi:3
[pii];10.2165/11536950-000000000-00000 [doi].
31. Abdo, A., C. Alfonso, G. Diaz, M. Wilford, M. Rocha, and N. Verdecia. 2011. Fatal 2009 pandemic
influenza A (H1N1) in a bone marrow transplant recipient. J.Infect.Dev.Ctries. 5:132–137.
32. Abed, Y., P. Simon, and G. Boivin. 2010. Prophylactic activity of intramuscular peramivir in mice
infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase
mutation. Antimicrob.Agents Chemother. 54:2819–2822. doi:AAC.01681-09 [pii];10.1128/
AAC.01681-09 [doi].
33. Accinelli, C., M. L. Sacca, J. Fick, M. Mencarelli, R. Lindberg, and B. Olsen. 2010. Dissipation and
removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 79:891–897.
doi:S0045-6535(10)00168-2 [pii];10.1016/j.chemosphere.2010.02.022 [doi].
34. Acosta, E. P. and D. W. Kimberlin. 2010. Determination of appropriate dosing of influenza drugs in
pediatric patients. Clin.Pharmacol.Ther. 88:704–707. doi:clpt2010173 [pii];10.1038/clpt.2010.173
[doi].
35. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010.
Oseltamivir dosing for influenza infection in premature neonates. J.Infect.Dis. 202:563–566.
doi:10.1086/654930 [doi].
36. Adalja, A. 2009. Optimization of antiviral prescribing for influenza. J.Hosp.Med. 4:E28. doi:10.1002/
jhm.538 [doi].
37. Adalja, A. A. 2010. Hematemesis in a 2009 H1N1 influenza patient. Am.J.Emerg.Med. 28:846–4.
doi:S0735-6757(09)00636-6 [pii];10.1016/j.ajem.2009.12.012 [doi].
38. Adams, S. and C. Sandrock. 2010. Avian influenza: update. Med.Princ.Pract. 19:421–432.
doi:000320299 [pii];10.1159/000320299 [doi].
212
BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011
39. Adisasmito, W., B. M. Hunter, R. Krumkamp, K. Latief, J. W. Rudge, P. Hanvoravongchai, and R. J.
Coker. 2011. Pandemic Influenza and Health System Resource Gaps in Bali: An Analysis Through
a Resource Transmission Dynamics Model. Asia Pac.J.Public Health. doi:1010539511421365
[pii];10.1177/1010539511421365 [doi].
40. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, F. Aghayev, M. Zaman, E. Bamgboye, N.
Dogan, R. Coker, K. Starzyk, N. A. Dreyer, and S. Toovey. 2010. Effectiveness of antiviral treatment
in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J.Infect.Dis. 202:1154–
1160. doi:10.1086/656316 [doi].
41. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, M. Zaman, E. Bamgboye, N. Dogan,
K. Starzyk, N. A. Dreyer, and S. Toovey. 2011. Strengthening observational evidence for antiviral
effectiveness in influenza A (H5N1). J.Infect.Dis. 204:810–811. doi:jir398 [pii];10.1093/infdis/jir398
[doi].
42. Aeffner, F., Z. P. Traylor, E. N. Yu, and I. C. Davis. 2011. Double-stranded RNA induces similar
pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. Am.J.Physiol Lung Cell Mol.
Physiol 301:L99–L109. doi:ajplung.00398.2010 [pii];10.1152/ajplung.00398.2010 [doi].
43. Agrati, C., C. Gioia, E. Lalle, E. Cimini, C. Castilletti, O. Armignacco, F. N. Lauria, F. Ferraro, M.
Antonini, G. Ippolito, M. R. Capobianchi, and F. Martini. 2010. Association of profoundly impaired
immune competence in H1N1v-infected patients with a severe or fatal clinical course. J.Infect.Dis.
202:681–689. doi:10.1086/655469 [doi].
44. Agrawal, A. S., M. Sarkar, S. Ghosh, T. Roy, S. Chakrabarti, R. Lal, A. C. Mishra, M. S. Chadha, and
M. Chawla-Sarkar. 2010. Genetic characterization of circulating seasonal Influenza A viruses (2005–
2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India. Infect.
Genet.Evol. 10:1188–1198. doi:S1567-1348(10)00207-8 [pii];10.1016/j.meegid.2010.07.019 [doi].
45. Agrawal, R., P. V. Rewatkar, G. R. Kokil, A. Verma, and A. Kalra. 2010. Oseltamivir: a first line defense
against swine flu. Med.Chem. 6:247–251. doi:BSP/MC/Epub/052 [pii].
46. Ai, H., F. Zheng, C. Zhu, T. Sun, L. Zhang, X. Liu, X. Li, G. Zhu, and H. Liu. 2010. Discovery of novel
influenza inhibitors targeting the interaction of dsRNA with the NS1 protein by structure-based virtual
screening. Int.J.Bioinform.Res.Appl. 6:449–460. doi:32Q1497545044537 [pii].
47. Ainai, A., T. Ichinohe, S. Tamura, T. Kurata, T. Sata, M. Tashiro, and H. Hasegawa. 2010. Zymosan
enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J.Med.Virol.
82:476–484. doi:10.1002/jmv.21694 [doi].
48. Akyuz, S., A. Yilmaz, M. Bulbul, O. Erdogan, R. Renda, and G. Demircin. 2011. Do immunosupressive
patients really have a severe outcome with H1N1 virus infection? J.Trop.Pediatr. 57:129–131.
doi:fmq054 [pii];10.1093/tropej/fmq054 [doi].
49. Al Aklabi, M. M., J. G. Weinkauf, A. Humar, and N. Ghorpade. 2010. Successful bilateral lung
transplantation in a patient with end-stage lung disease and positive novel influenza virus
(H1N1). J.Heart Lung Transplant. 29:898–899. doi:S1053-2498(10)00274-3 [pii];10.1016/j.
healun.2010.04.017 [doi].
50. Al-Baghli, F. and W. Al-Ateeqi. 2011. Encephalitis-associated pandemic A (H1N1) 2009 in a Kuwaiti
girl. Med.Princ.Pract. 20:191–195. doi:000321276 [pii];10.1159/000321276 [doi].
51. Albohy, A., S. Mohan, R. B. Zheng, B. M. Pinto, and C. W. Cairo. 2011. Inhibitor selectivity of a new
class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes. Bioorg.
Med.Chem. 19:2817–2822. doi:S0968-0896(11)00220-3 [pii];10.1016/j.bmc.2011.03.039 [doi].
52. Alfaresi, M., S. Albedwawi, and M. Hag-Ali. 2011. Detection of an oseltamivir-resistant pandemic
influenza A/H1N1 virus in the United Arab Emirates. Med.Princ.Pract. 20 :97–99. doi:000319926
[pii];10.1159/000319926 [doi].
213
WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA
53. Alioglu, B., A. Tasar, C. Ozen, B. Selver, and Y. Dallar. 2010. An experience of oseltamivir phosphate
(tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report.
Pathophysiol.Haemost.Thromb. 37:55–58. doi:000321379 [pii];10.1159/000321379 [doi].
54. Allen, I. C., C. B. Moore, M. Schneider, Y. Lei, B. K. Davis, M. A. Scull, D. Gris, K. E. Roney,
A. G. Zimmermann, J. B. Bowzard, P. Ranjan, K. M. Monroe, R. J. Pickles, S. Sambhara, and
J. P. Ting. 2011. NLRX1 protein attenuates inflammatory responses to infection by interfering
with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. Immunity. 34:854–865.
doi:S1074-7613(11)00226-3 [pii];10.1016/j.immuni.2011.03.026 [doi].
55. Alonso, M., B. Rodriguez-Sanchez, M. Giannella, P. Catalan, J. Gayoso, Lopez Bernaldo de
Quiros JC, E. Bouza, and d. Garcia, V. 2011. Resistance and virulence mutations in patients
with persistent infection by pandemic 2009 A/H1N1 influenza. J.Clin.Virol. 50:114–118.
doi:S1386-6532(10)00413-0 [pii];10.1016/j.jcv.2010.10.007 [doi].
56. Alonso-Tarres, C., C. Cortes-Lletget, S. Pintado, and A. Ricart. 2009. Severe influenza A (H1N1)v in
patients without any known risk factor. Crit Care 13:425. doi:cc8150 [pii];10.1186/cc8150 [doi].
57. Amayiri, N. and F. Madanat. 2011. Retrospective analysis of pediatric cancer patients diagnosed with
the pandemic H1N1 influenza infection. Pediatr.Blood Cancer 56:86–89. doi:10.1002/pbc.22805
[doi].
58. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention
and control of influenza in children, 2011–2012. Pediatrics. 2011 Oct;128(4):813–25. [doi] 10.1542/
peds.2011-2295. Epub 2011 Sep 2.
59. Ampofo, K., A. Herbener, A. J. Blaschke, C. Heyrend, M. Poritz, K. Korgenski, R. Rolfs, S. Jain, M.
G. Carvalho, F. C. Pimenta, J. Daly, E. O. Mason, C. L. Byington, and A. T. Pavia. 2010. Association
of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic
empyema in children in Utah. Pediatr.Infect.Dis.J. 29:905–909. doi:10.1097/INF.0b013e3181df2c70
[doi].
60. an der, H. M., U. Buchholz, G. Krause, G. Kirchner, H. Claus, and W. H. Haas. 2009. Breaking the
waves: modelling the potential impact of public health measures to defer the epidemic peak of novel
influenza A/H1N1. PLoS.One. 4:e8356. doi:10.1371/journal.pone.0008356 [doi].
61. An, S. C., L. L. Xu, F. D. Li, L. L. Bao, C. Qin, and Z. C. Gao. 2011. Triple combinations of
neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian
influenza pandemic. Med.Hypotheses 77:1054–1057. doi:S0306-9877(11)00454-3 [pii];10.1016/j.
mehy.2011.09.001 [doi].
62. Andersson, M. I., Z. G. Van, W. Preiser, E. Langenegger, and G. Theron. 2010. Pandemic flu (H1N1)
2009 and pregnancy. S.Afr.Med.J. 100:192, 194.
63. Andreas, L. B., M. T. Eddy, R. M. Pielak, J. Chou, and R. G. Griffin. 2010. Magic angle spinning NMR
investigation of influenza A M2(18–60): support for an allosteric mechanism of inhibition. J.Am.
Chem.Soc. 132:10958–10960. doi:10.1021/ja101537p [doi].
64. Angarone, M. 2011. Epidemiology and prevention of viral infections in patients with hematologic
malignancies. Infect.Disord.Drug Targets. 11:27–33. doi:BSP/ ID DT /E-Pub/-0035-10-5 [pii].
65. Anraku, M., S. Husain, T. Mazulli, and A. F. Pierre. 2011. Peri-operative novel 2009 H1N1 influenza
virus infection successfully treated with oseltamivir and zanamivir in a lung transplant recipient.
J.Heart Lung Transplant. 30:354. doi:S1053-2498(10)00670-4 [pii];10.1016/j.healun.2010.10.001
[doi].
214
BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011
66. Anton, A., A. A. Lopez-Iglesias, T. Tortola, I. Ruiz-Camps, P. Abrisqueta, L. Llopart, M. A. Marcos, M.
J. Martinez, G. Tudo, F. Bosch, A. Pahissa, M. T. de Anta, and T. Pumarola. 2010. Selection and viral
load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised
patient during treatment with neuraminidase inhibitors. Diagn.Microbiol.Infect.Dis. 68:214–219.
doi:S0732-8893(10)00301-9 [pii];10.1016/j.diagmicrobio.2010.08.003 [doi].
67. Anton, A., M. A. Marcos, M. J. Martinez, S. Ramon, R. Isanta, M. P. de, M. T. de Anta, and T.
Pumarola. 2010. Double (V27A/S31N) mutant 2009 pandemic influenza A (H1N1) virus isolated
from adamantane non-treated inmunocompetent child. Diagn.Microbiol.Infect.Dis. 67:114–115.
doi:S0732-8893(09)00510-0 [pii];10.1016/j.diagmicrobio.2009.12.019 [doi].
68. Appuhamy, R. D., F. H. Beard, H. N. Phung, C. E. Selvey, F. A. Birrell, and T. H. Culleton. 2010. The
changing phases of pandemic (H1N1) 2009 in Queensland: an overview of public health actions and
epidemiology. Med.J.Aust. 192:94–97. doi:app10898_fm [pii].
69. Arakawa, R., A. Bagashev, L. Song, K. Maurer, and K. E. Sullivan. 2010. Characterization of LRRFIP1.
Biochem.Cell Biol. 88:899–906. doi:o10-014 [pii];10.1139/O10-014 [doi].
70. Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and
A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with
pandemic (H1N1) influenza. CMAJ. 182:357–363. doi:cmaj.092127 [pii];10.1503/cmaj.092127
[doi].
71. Arias, C. F., M. Escalera-Zamudio, M. L. Soto-Del Rio, A. G. Cobian-Guemes, P. Isa, and S.
Lopez. 2009. Molecular anatomy of 2009 influenza virus A (H1N1). Arch.Med.Res. 40:643–654.
doi:S0188-4409(09)00196-9 [pii];10.1016/j.arcmed.2009.10.007 [doi].
72. Arinaminpathy, N. and A. R. McLean. 2009. Logistics of control for an influenza pandemic.
Epidemics. 1:83–88. doi:S1755-4365(09)00024-3 [pii];10.1016/j.epidem.2009.04.001 [doi].
73. Arora, R., R. Chawla, R. Marwah, P. Arora, R. K. Sharma, V. Kaushik, R. Goel, A. Kaur, M.
Silambarasan, R. P. Tripathi, and J. R. Bhardwaj. 2011. Potential of Complementary and
Alternative Medicine in Preventive Management of Novel H1N1 Flu (Swine Flu) Pandemic:
Thwarting Potential Disasters in the Bud. Evid.Based.Complement Alternat.Med. 2011:586506.
doi:10.1155/2011/586506 [doi].
74. Arya, V., W. W. Carter, and S. M. Robertson. 2010. The role of clinical pharmacology in supporting
the emergency use authorization of an unapproved anti-influenza drug, peramivir. Clin.Pharmacol.
Ther. 88:587–589. doi:clpt2010187 [pii];10.1038/clpt.2010.187 [doi].
75. Asai, N., Y. Ohkuni, A. Komatsu, R. Matsunuma, K. Nakashima, K. Ando, T. Iwasaki, D. Yasui, M.
Misawa, Y. Otsuka, and N. Kaneko. 2011. A case of asthma-complicated influenza myocarditis.
J.Infect.Chemother. 17:429–432. doi:10.1007/s10156-010-0128-7 [doi].
76. Ashraf, S., W. Kong, S. Wang, J. Yang, and R. Curtiss, III. 2011. Protective cellular responses elicited
by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella
vaccine. Vaccine 29:3990–4002. doi:S0264-410X(11)00448-8 [pii];10.1016/j.vaccine.2011.03.066
[doi].
77. Astrahan, P. and I. T. Arkin. 2011. Resistance characteristics of influenza to amino-adamantyls.
Biochim.Biophys.Acta 1808:547–553. doi:S0005-2736(10)00216-6 [pii];10.1016/j.
bbamem.2010.06.018 [doi].
78. Astrahan, P., R. Flitman-Tene, E. R. Bennett, M. Krugliak, C. Gilon, and I. T. Arkin. 2011.
Quantitative analysis of influenza M2 channel blockers. Biochim.Biophys.Acta 1808:394–398.
doi:S0005-2736(10)00302-0 [pii];10.1016/j.bbamem.2010.08.021 [doi].
79. Astray, M. J. and M. A. Lopaz Perez. 2009. [Swine flu (H1N1) pandemic: challenges and
repercussions for the health care system]. Farm.Hosp. 33:293–295. doi:13145787 [pii].
215
WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA
80. Atiee, G., K. Lasseter, S. Baughman, A. McCullough, P. Collis, A. Hollister, and J. Hernandez.
2011. Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral
Oseltamivir or Rimantadine in Humans. J.Clin.Pharmacol. doi:0091270011414574
[pii];10.1177/0091270011414574 [doi].
81. Attema, A. E., A. K. Lugner, and T. L. Feenstra. 2010. Investment in antiviral drugs: a real options
approach. Health Econ. 19:1240–1254. doi:10.1002/hec.1549 [doi].
82. Babon, J. A., J. Cruz, L. Orphin, P. Pazoles, M. D. Co, F. A. Ennis, and M. Terajima. 2009. Genome-
wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+)
T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum.Immunol. 70:711–
721. doi:S0198-8859(09)00144-X [pii];10.1016/j.humimm.2009.06.004 [doi].
83. Bagashev, A., M. C. Fitzgerald, D. F. Larosa, P. P. Rose, S. Cherry, A. C. Johnson, and K. E. Sullivan.
2010. Leucine-rich repeat (in Flightless I) interacting protein-1 regulates a rapid type I interferon
response. J.Interferon Cytokine Res. 30:843–852. doi:10.1089/jir.2010.0017 [doi].
84. Bagdure, D., D. J. Curtis, E. Dobyns, M. P. Glode, and S. R. Dominguez. 2010. Hospitalized children
with 2009 pandemic influenza A (H1N1): comparison to seasonal influenza and risk factors for
admission to the ICU. PLoS.One. 5:e15173. doi:10.1371/journal.pone.0015173 [doi].
85. Balannik, V., J. Wang, Y. Ohigashi, X. Jing, E. Magavern, R. A. Lamb, W. F. DeGrado, and L. H. Pinto.
2009. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants
of the M2 ion channel of influenza A virus. Biochemistry 48:11872–11882. doi:10.1021/bi9014488
[doi].
86. Balannik, V., P. Obrdlik, S. Inayat, C. Steensen, J. Wang, J. M. Rausch, W. F. DeGrado, B. Kelety, and
L. H. Pinto. 2010. Solid-supported membrane technology for the investigation of the influenza A virus
M2 channel activity. Pflugers Arch. 459:593–605. doi:10.1007/s00424-009-0760-1 [doi].
87. Balannik, V., V. Carnevale, G. Fiorin, B. G. Levine, R. A. Lamb, M. L. Klein, W. F. DeGrado, and L. H.
Pinto. 2010. Functional studies and modeling of pore-lining residue mutants of the influenza a virus
M2 ion channel. Biochemistry 49:696–708. doi:10.1021/bi901799k [doi].
88. Banerjee, D. and D. Kaul. 2010. Combined inhalational and oral supplementation of ascorbic
acid may prevent influenza pandemic emergency: a hypothesis. Nutrition 26:128–132.
doi:S0899-9007(09)00407-9 [pii];10.1016/j.nut.2009.09.015 [doi].
89. Bantia, S., D. Kellogg, C. D. Parker, and Y. S. Babu. 2010. Combination of peramivir and rimantadine
demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral
Res. 88:276–280. doi:S0166-3542(10)00743-6 [pii];10.1016/j.antiviral.2010.09.020 [doi].
90. Bantia, S., D. Kellogg, C. Parker, R. Upshaw, N. A. Ilyushina, and Y. S. Babu. 2011. A single
intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against
novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antiviral Res.
90:17–21. doi:S0166-3542(11)00029-5 [pii];10.1016/j.antiviral.2011.02.001 [doi].
91. Barak, S., A. Kushnir, E. Chulski, and D. Miron. 2010. Influenza A/H1N1 virus in very low-birth-weight
premature infant: case report. Am.J.Perinatol. 27:513–515. doi:10.1055/s-0030-1247606 [doi].
92. Baranovich, T., R. Saito, Y. Suzuki, H. Zaraket, C. Dapat, I. Caperig-Dapat, T. Oguma, I. I. Shabana,
T. Saito, and H. Suzuki. 2010. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses
in Japan during the 2008–2009 season. J.Clin.Virol. 47:23–28. doi:S1386-6532(09)00544-7
[pii];10.1016/j.jcv.2009.11.003 [doi].
93. Barbe, F., X. Saelens, D. Braeckmans, F. Lefevre, and K. V. Reeth. 2010. Role of IFN-alpha during
the acute stage of a swine influenza virus infection. Res.Vet.Sci. 88 :172–178. doi:S0034-
5288(09)00157-X [pii];10.1016/j.rvsc.2009.07.001 [doi].
216
BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011
94. Barber, M. R., J. R. Aldridge, Jr., R. G. Webster, and K. E. Magor. 2010. Association of RIG-I with
innate immunity of ducks to influenza. Proc.Natl.Acad.Sci.U.S.A 107 :5913–5918. doi:1001755107
[pii];10.1073/pnas.1001755107 [doi].
95. Barefoot, B. E., K. Athearn, C. J. Sample, and E. A. Ramsburg. 2009. Intramuscular immunization
with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides
post-exposure protection against lethal influenza challenge. Vaccine 28:79–89. doi:S0264-
410X(09)01472-8 [pii];10.1016/j.vaccine.2009.09.112 [doi].
96. Barik, S. 2010. siRNA for Influenza Therapy. Viruses. 2:1448–1457. doi:10.3390/v2071448
[doi];viruses-02-01448 [pii].
97. Barrero, P. R., M. Viegas, L. E. Valinotto, and A. S. Mistchenko. 2011. Genetic and phylogenetic
analyses of influenza A H1N1pdm virus in Buenos Aires, Argentina. J.Virol. 85:1058–1066.
doi:JVI.00936-10 [pii];10.1128/JVI.00936-10 [doi].
98. Barrett, C., K. Bisset, J. Leidig, A. Marathe, and M. Marathe. 2011. Economic and social impact
of influenza mitigation strategies by demographic class. Epidemics. 3:19–31. doi:10.1016/j.
epidem.2010.11.002 [doi].
99. Barrionuevo, R. L., A. C. Masuet, and J. M. Ramon Torrell. 2009. [Effects of influenza vaccination
on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study]. Gac.Sanit.
23:315–321. doi:S0213-9111(09)00093-4 [pii];10.1016/j.gaceta.2008.10.011 [doi].
100. Barry, J. M. 2009. Observations on past influenza pandemics. Disaster.Med.Public Health Prep. 3
Suppl 2:S95–S99. doi:10.1097/DMP.0b013e3181be82c5 [doi].
101. Barry, M. A. 2010. A 29-year-old woman with flu-like symptoms: review of influenza diagnosis and
treatment. JAMA 304:671–678. doi:304/6/671 [pii];10.1001/jama.304.6.671 [doi].
102. Bassaganya-Riera, J., R. Song, P. C. Roberts, and R. Hontecillas. 2010. PPAR-gamma activation
as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol. 23:343–352.
doi:10.1089/vim.2010.0016 [doi].
103. Baum, A. and A. Garcia-Sastre. 2011. Differential recognition of viral RNA by RIG-I. Virulence.
2:166–169. doi:15481 [pii].
104. Baum, S. G. 2009. Oseltamivir resistance: what does it mean clinically? Clin.Infect.Dis. 49:1836–
1837. doi:10.1086/648425 [doi].
105. Bautista, E., T. Chotpitayasunondh, Z. Gao, S. A. Harper, M. Shaw, T. M. Uyeki, S. R. Zaki, F. G.
Hayden, D. S. Hui, J. D. Kettner, A. Kumar, M. Lim, N. Shindo, C. Penn, and K. G. Nicholson. 2010.
Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N.Engl.J.Med. 362:1708–1719.
doi:362/18/1708 [pii];10.1056/NEJMra1000449 [doi].
106. Baz, M., Y. Abed, P. Simon, M. E. Hamelin, and G. Boivin. 2010. Effect of the neuraminidase mutation
H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent
human influenza A(H1N1) viruses. J.Infect.Dis. 201:740–745. doi:10.1086/650464 [doi].
107. Bearman, G. M., S. Shankaran, and K. Elam. 2010. Treatment of severe cases of pandemic (H1N1)
2009 influenza: review of antivirals and adjuvant therapy. Recent Pat Antiinfect.Drug Discov.
5:152–156. doi:BSP/PRI/EPUB/00004 [pii].
108. Becker, N. G. and D. Wang. 2011. Can antiviral drugs contain pandemic influenza transmission?
PLoS.One. 6:e17764. doi:10.1371/journal.pone.0017764 [doi].
109. Beigel, J. H. 2010. ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA
INFECTION. Drugs Future. 35:385–392. doi:10.1358/dof.2010.035.05.1487081 [doi].
217
WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA
110. Beigi, R. H., K. Han, R. Venkataramanan, G. D. Hankins, S. Clark, M. F. Hebert, T.
Easterling, A. Zajicek, Z. Ren, D. R. Mattison, and S. N. Caritis. 2011. Pharmacokinetics of
oseltamivir among pregnant and nonpregnant women. Am.J.Obstet.Gynecol. 204:S84–S88.
doi:S0002-9378(11)00311-5 [pii];10.1016/j.ajog.2011.03.002 [doi].
111. Beliakova, N. V., S. V. Al’khovskii, E. S. Shevchenko, A. G. Prilipov, D. D. Abramov, L. V. Kolobukhina,
L. N. Merkulova, S. V. Trushakova, and E. I. Burtseva. 2010. [Molecular genetic studies of the
susceptibility of epidemic influenza A(H1N1) virus strains isolated in the 2006–2009 seasons in
Russia to oseltamivir (Tamiflu)]. Vopr.Virusol. 55:10–13.
112. Belle, J., H. Cohen, N. Shindo, M. Lim, A. Velazquez-Berumen, J. B. Ndihokubwayo, and M. Cherian.
2010. Influenza preparedness in low-resource settings: a look at oxygen delivery in 12 African
countries. J.Infect.Dev.Ctries. 4:419–424.
113. Bellissima, P. and G. Bellissima . 2011. [Pulmonary complications from pandemic AH1N1 influenza:
clinical-radiological features]. Infez.Med. 19:20–27.
114. Belolipetskaia, V. G., S. V. Blagodatskikh, E. A. Zhabina, D. A. Kibalchich, D. F. Guranda, N. A.
Belolipetskii, and L. I. Rudenko. 2011. [Comparative pharmacokinetics of antigrippin-maximum
administered in capsules and powder for preparing solutions]. Eksp.Klin.Farmakol. 74:38–40.
115. Bender, M. and C. Bernheisel. 2010. Fever, cough, and hypoxia in a pregnant woman. J.Fam.Pract.
59:E9–11. doi:jfp_5904j [pii].
116. Benfield, C. T., J. W. Lyall, and L. S. Tiley. 2010. The cytoplasmic location of chicken mx is not
the determining factor for its lack of antiviral activity. PLoS.One. 5:e12151. doi:10.1371/journal.
pone.0012151 [doi].
117. Bennack, E. and U. Holzgrabe. 2010. [Emergency admission of peramivir in the U.S.A]. Pharm.
Unserer Zeit 39:9–10. doi:10.1002/pauz.200990126 [doi].
118. Bennett, S., R. N. Gunson, A. MacLean, R. Miller, and W. F. Carman. 2011. The validation of a
real-time RT-PCR assay which detects influenza A and types simultaneously for influenza A H1N1
(2009) and oseltamivir-resistant (H275Y) influenza A H1N1 (2009). J.Virol.Methods 171:86–90.
doi:S0166-0934(10)00360-5 [pii];10.1016/j.jviromet.2010.10.005 [doi].
119. Bergstrom, K. G. 2010. Tamiflu: what dermatologists need to know. J.Drugs Dermatol. 9:76–78.
120. Bernaola, E. 2009. [Why vaccinate to children against the flu]. Rev.Esp.Quimioter. 22 Suppl 1:15–17.
doi:GripeEnriqueBernaola [pii].
121. Berthoud, T. K., M. Hamill, P. J. Lillie, L. Hwenda, K. A. Collins, K. J. Ewer, A. Milicic, H. C. Poyntz,
T. Lambe, H. A. Fletcher, A. V. Hill, and S. C. Gilbert. 2011. Potent CD8+ T-cell immunogenicity
in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin.Infect.Dis. 52:1–7.
doi:ciq015 [pii];10.1093/cid/ciq015 [doi].
122. Bertisch, B., P. Vernazza, and K. Boggian. 2010. Patients with influenza A/H1N1v- associated
pneumonia: the perspective of a tertiary care hospital in Switzerland. Swiss.Med.Wkly. 140:w13069.
doi:smw-13069 [pii];10.4414/smw.2010.13069 [doi].
123. Bewick, T., P. Myles, S. Greenwood, J. S. Nguyen-Van-Tam, S. J. Brett, M. G. Semple, P. J.
Openshaw, B. Bannister, R. C. Read, B. L. Taylor, J. McMenamin, J. E. Enstone, K. G. Nicholson, and
W. S. Lim. 2011. Clinical and laboratory features distinguishing pandemic H1N1 influenza-related
pneumonia from interpandemic community-acquired pneumonia in adults. Thorax 66:247–252.
doi:thx.2010.151522 [pii];10.1136/thx.2010.151522 [doi].
124. Biatto, J. F., E. L. Costa, L. Pastore, E. G. Kallas, D. Deheinzelin, and G. Schettino. 2010. Prone
position ventilation, recruitment maneuver and intravenous zanamivir in severe refractory hypoxemia
caused by influenza A (H1N1). Clinics.(Sao Paulo) 65:1211–1213. doi:S1807-59322010001100026
[pii].
218
BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011
125. Bijl, D. 2011. Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects.
Int.J.Risk Saf Med. 23:65–71. doi:P267TH7832P32713 [pii];10.3233/JRS-2011-0521 [doi].
126. Bing, F. H., J. Liu, Z. Li, G. B. Zhang, Y. F. Liao, J. Li, and C. Y. Dong. 2009. Anti-influenza-virus
activity of total alkaloids from Commelina communis L. Arch.Virol. 154:1837–1840. doi:10.1007/
s00705-009-0503-9 [doi].
127. Bloom, J. D., L. I. Gong, and D. Baltimore. 2010. Permissive secondary mutations enable the
evolution of influenza oseltamivir resistance. Science 328:1272–1275. doi:328/5983/1272
[pii];10.1126/science.1187816 [doi].
128. Bodewes, R., J. H. Kreijtz, M. L. Hillaire, M. M. Geelhoed-Mieras, R. A. Fouchier, A. D. Osterhaus,
and G. F. Rimmelzwaan. 2010. Vaccination with whole inactivated virus vaccine affects the induction
of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific
CD8+ T-cell responses in mice. J.Gen.Virol. 91:1743–1753. doi:vir.0.020784-0 [pii];10.1099/
vir.0.020784-0 [doi].
129. Bogoch, I. I., J. R. Andrews, F. M. Marty, and E. L. Hohmann. 2011. HIV-1 and 2009 H1N1 influenza
A in adults. J.Acquir.Immune.Defic.Syndr. 56:e111–e113. doi:10.1097/QAI.0b013e31820a9afb
[doi];00126334-201104010-00016 [pii].
130. Boibieux, A. 2010. [Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus]. Ann.Fr.Anesth.
Reanim. 29:85–86. doi:S0750-7658(10)00006-7 [pii];10.1016/j.annfar.2010.01.005 [doi].
131. Boltz, D. A., B. Douangngeun, P. Phommachanh, S. Sinthasak, R. Mondry, C. Obert, P. Seiler, R.
Keating, Y. Suzuki, H. Hiramatsu, E. A. Govorkova, and R. G. Webster. 2010. Emergence of H5N1
avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants
in Lao People’s Democratic Republic. J.Gen.Virol. 91:949–959. doi:vir.0.017459-0 [pii];10.1099/
vir.0.017459-0 [doi].
132. Boltz, D. A., J. R. Aldridge, Jr., R. G. Webster, and E. A. Govorkova. 2010. Drugs in development for
influenza. Drugs 70:1349–1362. doi:1 [pii];10.2165/11537960-000000000-00000 [doi].
133. Bonneux, L. 2009. [No evidence of fewer influenza complications with oseltamivir]. Ned.Tijdschr.
Geneeskd. 153:A1127.
134. Bonneux, L. and D. W. Van. 2010. Preventing iatrogenic pandemics of panic. Do it in a NICE way.
BMJ 340:c3065.
135. Bottcher-Friebertshauser, E., D. A. Stein, H. D. Klenk, and W. Garten. 2011. Inhibition of influenza
virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer
targeting the hemagglutinin-activating protease TMPRSS2. J.Virol. 85:1554–1562. doi:JVI.01294-10
[pii];10.1128/JVI.01294-10 [doi].
136. Boudreault, A. A., H. Xie, W. Leisenring, J. Englund, L. Corey, and M. Boeckh. 2011. Impact
of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell
transplant patients infected with influenza virus. Biol.Blood Marrow Transplant. 17:979–986.
doi:S1083-8791(10)00394-0 [pii];10.1016/j.bbmt.2010.09.014 [doi].
137. Boukhvalova, M. S., T. B. Sotomayor, R. C. Point, L. M. Pletneva, G. A. Prince, and J. C. Blanco.
2010. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and
pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections
in the cotton rat Sigmodon hispidus model. J.Interferon Cytokine Res. 30:229–242. doi:10.1089/
jir.2009.0025 [doi].
138. Bouslama, L., K. Hayashi, J. B. Lee, A. Ghorbel, and T. Hayashi. 2011. Potent virucidal effect
of pheophorbide a and pyropheophorbide a on enveloped viruses. J.Nat.Med. 65:229–233.
doi:10.1007/s11418-010-0468-8 [doi].
219
WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA
139. Boutolleau, D., N. Houhou, C. Deback, H. Agut, and F. Brun-Vezinet. 2010. Detection of pandemic
(H1N1) 2009 virus in patients treated with oseltamivir. Emerg.Infect.Dis. 16:351–352. doi:10.3201/
eid1602.091328 [doi].
140. Bozzo, P., N. Djokanovic, and G. Koren. 2009. H1N1 influenza in pregnancy: risks, vaccines, and
antivirals. J.Obstet.Gynaecol.Can. 31:1172–1175.
141. Bramley, A. M., J. Bresee, and L. Finelli. 2009. Pediatric influenza. Pediatr.Nurs. 35:335–345.
142. Brass, A. L., I. C. Huang, Y. Benita, S. P. John, M. N. Krishnan, E. M. Feeley, B. J. Ryan, J. L. Weyer,
L. van der Weyden, E. Fikrig, D. J. Adams, R. J. Xavier, M. Farzan, and S. J. Elledge. 2009. The
IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue
virus. Cell 139:1243–1254. doi:S0092-8674(09)01564-5 [pii];10.1016/j.cell.2009.12.017 [doi].
143. Bresci, S., B. Borchi, S. Ambu, G. Taccetti, C. Braggion, and F. Leoncini. 2010. Case report: cystic
fibrosis, lung transplantation, and the novel H1N1 flu. Transplant.Proc. 42:2270–2273. doi:S0041-
1345(10)00686-X [pii];10.1016/j.transproceed.2010.05.028 [doi].
144. Brook, I. 2011. Microbiology of sinusitis. Proc.Am.Thorac.Soc. 8:90–100. doi:8/1/90 [pii];10.1513/
pats.201006-038RN [doi].
145. Brookes, D. W., S. Miah, A. Lackenby, L. Hartgroves, and W. S. Barclay. 2011. Pandemic H1N1
2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small
compromise in enzyme activity and viral fitness. J.Antimicrob.Chemother. 66:466–470. doi:dkq486
[pii];10.1093/jac/dkq486 [doi].
146. Brown, A. N., J. B. Bulitta, J. J. McSharry, Q. Weng, J. R. Adams, R. Kulawy, and G. L. Drusano.
2011. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated
by a mathematical model. Antimicrob.Agents Chemother. 55:1747–1753. doi:AAC.01629-10
[pii];10.1128/AAC.01629-10 [doi].
147. Brown, A. N., J. J. McSharry, Q. Weng, E. M. Driebe, D. M. Engelthaler, K. Sheff, P. S. Keim, J.
Nguyen, and G. L. Drusano. 2010. In vitro system for modeling influenza A virus resistance under
drug pressure. Antimicrob.Agents Chemother. 54:3442–3450. doi:AAC.01385-09 [pii];10.1128/
AAC.01385-09 [doi].
148. Brown, A. N., J. J. McSharry, Q. Weng, J. R. Adams, R. Kulawy, and G. L. Drusano. 2011. Zanamivir,
at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus
in an in vitro hollow-fiber infection model system. Antimicrob.Agents Chemother. 55:1740–1746.
doi:AAC.01628-10 [pii];10.1128/AAC.01628-10 [doi].
149. Brown, C. M. 2010. Severe influenza A virus (H1N1) infection in pregnancy. Obstet.Gynecol.
115:412–414. doi:10.1097/AOG.0b013e3181cbc7c5 [doi];00006250-201002001-00006 [pii].
150. Brunner, J., J. Bogner, and U. Seybold. 2011. [Flu-like illness – how to rule in and manage influenza].
MMW.Fortschr.Med. 153:29–31, 33.
151. Bryans, J. T., W. W. Zent, R. R. Grunert, and D. C. Boughton. 1966. I-adamantanamine hydrochloride
prophylaxis for experimentally induced A/equine 2 influenza virus infection. Nature 212:1542–1544.
152. Buchholz, U., S. Brockmann, S. Duwe, B. Schweiger, H. M. an der, B. Reinhardt, and S. Buda. 2010.
Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza
A(H1N1) viruses, Germany, 2007–8. Euro.Surveill 15.
153. Burch, J., M. Paulden, S. Conti, C. Stock, M. Corbett, N. J. Welton, A. E. Ades, A. Sutton, N. Cooper,
A. J. Elliot, K. Nicholson, S. Duffy, C. McKenna, L. Stewart, M. Westwood, and S. Palmer . 2009.
Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health
Technol.Assess. 13:1–iv. doi:10.3310/hta13580 [doi].
220